AxoGen (AXGN) Receives a Buy from H.C. Wainwright
TipRanks (Fri, 27-Feb 6:36 AM ET)
AxoGen (AXGN) Gets a Buy from Canaccord Genuity
TipRanks (Wed, 25-Feb 7:40 AM ET)
Axogen targets at least 18% revenue growth in 2026 as BLA milestone strengthens market position
Seeking Alpha News (Tue, 24-Feb 11:38 AM ET)
AxoGen Posts Strong Growth and Raises Capital With Offering
TipRanks (Tue, 24-Feb 7:37 AM ET)
AxoGen Non-GAAP EPS of $0.07 misses by $0.03, revenue of $59.9M in-line
Seeking Alpha News (Tue, 24-Feb 7:10 AM ET)
Axogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results
Globe Newswire (Tue, 24-Feb 7:00 AM ET)
Here are the major earnings before the open Tuesday
Seeking Alpha News (Mon, 23-Feb 6:00 PM ET)
AxoGen Q4 2025 Earnings Preview
Seeking Alpha News (Mon, 23-Feb 11:10 AM ET)
Lake Street Keeps Their Buy Rating on AxoGen (AXGN)
TipRanks (Mon, 23-Feb 9:55 AM ET)
Analysts Offer Insights on Healthcare Companies: AxoGen (AXGN) and Guardant Health (GH)
TipRanks (Mon, 23-Feb 9:40 AM ET)
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
Axogen trades on the NASDAQ stock market under the symbol AXGN.
As of February 27, 2026, AXGN stock price declined to $31.03 with 409,903 million shares trading.
AXGN has a beta of 1.43, meaning it tends to be more sensitive to market movements. AXGN has a correlation of 0.13 to the broad based SPY ETF.
AXGN has a market cap of $1.56 billion. This is considered a Small Cap stock.
Last quarter Axogen reported $60 million in Revenue and $.07 earnings per share. This beat revenue expectation by $4,500 and exceeded earnings estimates by $.03.
In the last 3 years, AXGN traded as high as $36.00 and as low as $3.45.
The top ETF exchange traded funds that AXGN belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
AXGN has outperformed the market in the last year with a return of +59.5%, while the SPY ETF gained +16.1%. In the last 3 month period, AXGN beat the market returning +8.7%, while SPY returned +0.8%. However, in the most recent 2 weeks AXGN has underperformed the stock market by returning -4.8%, while SPY returned +0.3%.
AXGN support price is $30.88 and resistance is $32.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AXGN shares will trade within this expected range on the day.